Eli Lilly | LLY - Trade Debtors



Eli Lilly reported $17.21B in Trade Debtors for its fiscal quarter ending in June of 2025.


Trade Debtors Change Date
AbbVie USD 12.48B 1.56B Mar/2025
Abbott USD 10.23B 562M Jun/2025
ALKERMES USD 356.33M 34.58M Jun/2025
Amgen USD 8.7B 569M Jun/2025
AstraZeneca USD 16.24B 1.42B Jun/2025
Baxter International USD 1.65B 84M Mar/2025
Biogen USD 2.08B 87.5M Jun/2025
Bristol-Myers Squibb USD 15.1B 515M Jun/2025
Drreddys Laboratories INR 115.44B 3.95B Jun/2025
Eli Lilly USD 17.21B 3.2B Jun/2025
Gilead Sciences USD 4.78B 393M Jun/2025
GlaxoSmithKline GBP 7.7B 196M Jun/2025
Glaxosmithkline GBP 7.7B 372M Jun/2025
J&J USD 16.02B 1.18B Mar/2025
Medtronic USD 6.52B 400M Apr/2025
Merck USD 12.72B 1.14B Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Novartis USD 9.18B 451M Jun/2025
Novartis USD 9.18B 1.62B Jun/2025
Novo Nordisk 90.28B 3.92B Jun/2025
Perrigo USD 678.2M 38.6M Jun/2025
Pfizer USD 16.09B 1.35B Jun/2025
Prestige Brands USD 168.4M 25.89M Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Roche Holding CHF 13.46B 984M Dec/2024
Sanofi 8.21B 7.76B Jun/2025
Sanofi 8.21B 2.42B Jun/2025
United Therapeutics USD 379.3M 57.3M Jun/2025
Zoetis USD 1.54B 179M Jun/2025